It was recently reported that Oncogene-addicted NSCLC with CNS and/or extra-CNS oligoprogressive disease on relevant targeted therapies is suitable for local ablative therapy and continuation of the targeted agents, and is associated with more than 6 months of additional disease control.[22] Moreover, Yu et al[23] reported EGFR-mutant lung cancers with acquired resistance to EGFR-TKI therapy are amenable to local therapy including surgery or radiation followed by continued targeted therapy, and 10 months additional disease control was observed. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.